ReviewThe international journal of neuropsychopharmacology2025
A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPARγ receptors.
Review in The international journal of neuropsychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Cannabidiol and Alcohol Use Disorders: An Updated Review of Therapeutic Potential.Alcohol, clinical & experimental research · 2026Review
- Cannabis and Cannabinoids: The Medical Potential of Cannabidiol in Mental and Neurological Disorders.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Sex differences in the disposition of cannabidiol and its metabolites in mice.Journal of cannabis research · 2026Article
- Medicinal Plants for Major Depressive Disorder.Brain sciences · 2026Review
- Antidepressant-like effects of cannabidiol when combined with temozolomide in adult rats.Frontiers in pharmacology · 2026Article
- Interplay between the HPA axis and inflammation as mechanisms therapeutic targets ofFrontiers in pharmacology · 2026Review
- The Endocannabinoid System in Human Disease: Molecular Signaling, Receptor Pharmacology, and Therapeutic Innovation.International journal of molecular sciences · 2025Review
- Cannabidiol reverses depression-like behaviors by enhancing hippocampal synaptic plasticity in rats with chronic restraint stress.Veterinary world · 2025Article
- Adolescent cannabidiol treatment produces antidepressant-like effects without compromising long-term cognition in rats.Pharmacological reports : PR · 2025Article
- Article
- Demographic features, health status, and behavioral changes associated with cannabidiol use in the Dog Aging Project.Frontiers in veterinary science · 2025Article
- Preventive beneficial effects of cannabidiol in a reserpine-induced progressive model of parkinsonism.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDepression is a prevalent and disabling disorder that poses serious problems in mental health care, and rapid antidepressants are novel treatments for this disorder. Cannabidiol (CBD), a nonintoxicating phytocannabinoid, is thought to have therapeutic potential due to its important neurological and anti-inflammatory properties. Despite major advances in pharmacotherapy in experimental animals, the exact mechanism of antidepressant-like effects remains to be elucidated.
methodsIn this paper, we review the current state of knowledge on the antidepressant properties of CBD in numerous experimental and clinical studies.
resultsAccumulating evidence suggests that CBD has antidepressant properties in humans and animals with few side effects, suggesting that CBD may be a potential antidepressant. Furthermore, we discuss that CBD may therefore provide a potential treatment to exert antidepressant-like effects through various molecular targets, reducing inflammation, and enhancing neurogenesis.
conclusionsTaken together with the growing popularity of CBD as a medicine, these findings extend the limited knowledge on the antidepressant effects of CBD. This potentially opens up new therapeutic means for the patients with depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.